SpringerLink
Log in

The Potential of Interferons in Malignant Disease

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Ahre A, Bjoekholm M, Mellstedt H, Brenning G, Engstedt L, et al. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the myeloma group of central Sweden. Cancer Treatment and Research 68: 1331–1338,1984

    CAS  Google Scholar 

  • Akiyama Y, Lubeck M, Steplewski Z, Koprowski H. Induction of mouse IgG2a and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon. Cancer Research 44: 5127–5131, 1984

    PubMed  CAS  Google Scholar 

  • Apostolov K, Barker W. The effects of interferon on the fatty acids in uninfected cells. FEBS Letters 126: 261–264, 1981

    Article  PubMed  CAS  Google Scholar 

  • Apostolov K, Barker W, Catovsky D, Goldman J, Matutes E. Reduction in the stearic to oleic acid ratio in leukemic cells: a possible chemical marker of malignancy. Blut 50: 349–354, 1985

    Article  PubMed  CAS  Google Scholar 

  • Billiau A, DeSomer P, Edy VG, DeClerco E, Heremans H. Human fibfoblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans. Antimicrobial Agents and Chemotherapy 16: 56–63, 1979

    Article  PubMed  CAS  Google Scholar 

  • D’Acquisto R, Markman M, Hakes T, Rabin S, Haskins W, et al. A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. Journal of Clinical Oncology 6: 689–695, 1988

    PubMed  Google Scholar 

  • Edmonson JH, Long HJ, Frytak S, Smithson WA, Itri LM. Phase II study of recombinant alpha-2a interferon in patients with advanced bone sarcomas. Cancer Treatment Reports 71: 747–748, 1987

    PubMed  CAS  Google Scholar 

  • Finter N.B. Standardization of assay of interferons. Methods of Enzymology 78: 14–22, 1981

    Article  CAS  Google Scholar 

  • Foon KA, Bottino GC, Abrams PG, Fer MF, Longo DL, et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. American Journal of Medicine 78: 216–220, 1985

    Article  PubMed  CAS  Google Scholar 

  • Gresser I. How does interferon inhibit tumor growth? Philosophical Transactions of the Royal Society of London, B299: 69–76, 1982

    Article  Google Scholar 

  • Gresser I, Maury C, Bronty-Boye D. Mechanism of the antitumor effects of interferon in mice. Nature 239: 167, 1972

    Article  PubMed  CAS  Google Scholar 

  • Gutterman JU, Blumenschein GR, Alexanian R, Yap H-U, Buzdar AU, et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Annals of Internal Medicine 93: 399–406, 1980

    PubMed  CAS  Google Scholar 

  • Hasse KD, Lange OF, Scheef W. Interferon-7 treatment of metastasized malignant melanoma. Anticancer Research 7: 335–336, 1987

    Google Scholar 

  • Isaacs A, Lindermann J. Virus interference. I. The interferon. Proceedings of the Royal Society of Britain 147: 258–267, 1957

    Article  CAS  Google Scholar 

  • Itoh K, Shiba K, Shimizu Y, Suzuki R, Kumagai K. Generation of activated killer (AK) cell by recombinant interleukin 2 (IL2) in collaboration with interferon-γ (IFN-γ). Journal of Immunology 134: 3124–3129, 1985

    CAS  Google Scholar 

  • Kirkwood JM, Harris JE, Vera R, Sandler S, Fisher DS, et al. A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Research 45: 863–871, 1985

    PubMed  CAS  Google Scholar 

  • Kleinerman ES, Kurzrock R, Wyatt D, Quesda JR, Gutterman JU, et al. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant γ-inteferon. Cancer Research 46: 5401–5405, 1986

    PubMed  CAS  Google Scholar 

  • Kurzrock R, Talpaz M, Kantarjian HM, Wealters R, Saks S, et al. Therapy of chronic myelogenous leukemia with recombinant interferon-γ. Blood 70: 943–947, 1987

    PubMed  CAS  Google Scholar 

  • Lin SL, Greene JJ, Ts’o POP, Carter WA. Sensitivity and resistance of human tumor cells to interferon and rIrC. Nature 297: 417, 1982

    Article  PubMed  CAS  Google Scholar 

  • Ludwig H, Cortelezzi A, Scheithauer W, Van Camp BGK, Kuzmits R, et al. Recombinant interferon alpha-2c versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. European Journal of Cancer and Clinical Oncology 22: 1111–1116, 1986

    Article  CAS  Google Scholar 

  • McLeod GRC, Thomson DB, Hersey P. Recombinant interferon alpha-2a in advanced malignant melanoma: a phase I-II study in combination with DTIC. International Journal of Cancer (Suppl.)I: 31–35, 1987

  • Nagai M, Arai T, Kohno S, Kohase M. Interferon therapy for malignant brain tumors. In Kono R & Vilcek J (Eds) The clinical potential of interferons, pp. 257–273, University of Tokyo Press, Tokyo, 1982

    Google Scholar 

  • Ohno R. Interferon in the treatment of multiple myeloma. International Journal of Cancer (Suppl.) I: 14–20, 1987

    Google Scholar 

  • Ohno R. Clinical trial of interferons in malignant lymphoma. Journal of Adult Disease (Japan) 18: 627–631, 1988

    Google Scholar 

  • Papermaster VM, Baron S. Immune interferon for clinical trials: conditions for induction, purification and stability. Texas Reproductive Biology and Medicine 41: 672–680, 1981–1982

    CAS  Google Scholar 

  • Quesada JR, Rios A, Swanson D. Anti-tumour activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. Journal of Clinical Oncology 3: 1522–1528, 1985

    PubMed  CAS  Google Scholar 

  • Quesada JR, Swanson DA, Trindade A, Gutterman JU. Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Research 43: 940–947, 1983

    PubMed  CAS  Google Scholar 

  • Rohatiner AZS, Balkwill FR, Griffin DB. A phase 1 study of human lymphblastoid interferon administered by continuous intravenous infusion. Cancer Chemotherapy and Pharmacology 9: 97–102, 1982

    Article  PubMed  CAS  Google Scholar 

  • Sakurai M, Iigo M, Tamura T, Otsu A, Sasaki Y, et al. Comparative study of the antitumor effect of two types of murine recombinant interferons (β) and (γ), against B16-F10 melanoma. Cancer Immunology and Immunotherapy 26: 109–113, 1988

    PubMed  CAS  Google Scholar 

  • Sarna CP, Figlin RA, Pertcheck M. Phase II study of betaseron (βser17-interferon) as treatment of advanced malignant melanoma. Journal of Biological Response Modifiers 6: 375–378, 1987

    PubMed  CAS  Google Scholar 

  • Sikora K. Interferon and malignant disease. British Journal of Clinical Practice 40: 406–410, 1986

    PubMed  CAS  Google Scholar 

  • Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma: a clinical and pathological study of 309 cases. Cancer 28: 1165–1177, 1971

    Article  PubMed  CAS  Google Scholar 

  • Smith OB, Scarffe JH, Wagstaff J, Johnson RJ. Phase II trial of rDNA alpha 2b interferon in patients with malignant carcinoid tumor. Cancer Treatment Reports 71: 1265–1266, 1987

    PubMed  CAS  Google Scholar 

  • Sone S, Tandon P, Utsugi T, Ogawara M, Shimizu E, et al. Synergism of recombinant human interferon gamma with lipo-some-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes. International Journal of Cancer 38: 495–500, 1986

    Article  CAS  Google Scholar 

  • Strander H. Interferons: anti-neoplastic drug? Blut 35: 277–288, 1977

    Article  PubMed  CAS  Google Scholar 

  • Strander H. Interferon treatment of human neoplasia. Advances in Cancer Research 1–265, 1986a

  • Strander H. Interferon treatment of malignant disease today and in the future. Acta Gastro-Enterologica Belgica 49(5): 501–505, 1986b

    PubMed  CAS  Google Scholar 

  • Suzuki N, Suzuki H. Suppression of UV mutagenicity by human interferon. Mutagenicity Research 202: 179–183, 1988

    CAS  Google Scholar 

  • Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69: 1280–1288, 1987

    PubMed  CAS  Google Scholar 

  • Tamura K, Makino S, Araki Y, Imamura T, Seita M. Recombinant interferon beta and gamma in the treatment of adult T-cell leukemia. Cancer 59: 1059–1062, 1987

    Article  PubMed  CAS  Google Scholar 

  • Vallbracht A, Treuner J, Flehming B, Joester KE, Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289: 496–497, 1981

    Article  PubMed  CAS  Google Scholar 

  • Von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61: 1071–1074, 1988

    Article  Google Scholar 

  • Wallach D, Fellous M, Revel M. Preferential effect of γ-interferon on the synthesis of HLA antigens and their mRNA in human cells. Nature 299: 833–836, 1982

    Article  PubMed  CAS  Google Scholar 

  • Weiner LM, Moldofsky PJ, Gatenby RA, O’Dwyer J, O’Brien J, et al. Antibody delivery and effector cell activation in a phase II trial of recombinant γ-interferon and the murine monoclonal antibody CO 17-IA in advanced colorectal carcinoma. Cancer Research 48: 2568–2573, 1988a

    PubMed  CAS  Google Scholar 

  • Weiner LM, Steplewski Z, Koprowski H, Litwin S, Comis RL. Divergent dose-related effects of γ-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes. Cancer Research 48: 1042–1046, 1988b

    PubMed  CAS  Google Scholar 

  • Worman CP, Barker WR, Apostolov K. Saturation index of blood cell membrane fatty acids before and after IFN treatment in hairy cell leukemia. Leukemia 1: 379–382, 1987

    PubMed  CAS  Google Scholar 

  • Yamasaki T, Okita K, Kurokawa F, Furukawa Y, Takemoto Y, et al. Antiproliferative effect of human interferon with/without polyprenoic acid on human hepatoma cells in vitro in nude mice. Acta Hepatologica Japonica 29: 56–64, 1988

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine and Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi-pref, 755, Japan

    Kiwamu Okita & Toshio Kaneko

Authors
  1. Kiwamu Okita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshio Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okita, K., Kaneko, T. The Potential of Interferons in Malignant Disease. Drugs 39, 1–6 (1990). https://doi.org/10.2165/00003495-199039010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199039010-00001

Keywords

Search

Navigation